primary endpoints

Related by string. primary endpoint * pri mary . PRIMARY . Primary : Primary Care Trust . Primary Care Trusts . Primary Leaving Examinations / Endpoint . Endpoints . EndPoint : Secondary endpoints include . primary efficacy endpoint . secondary efficacy endpoints * Meets Primary Endpoint . Meet Primary Endpoint . Achieves Primary Endpoint . specified primary endpoint *

Related by context. Frequent words. (Click for all words.) 83 primary endpoint 80 primary efficacy endpoint 76 secondary endpoints 74 secondary endpoint 64 non inferiority 64 demonstrated statistically significant 62 clinical endpoints 58 evaluable 58 ACTEMRA 58 clinically meaningful 57 statistically significant improvement 57 statistical significance 57 pharmacodynamic 57 tolerability 56 evaluable patients 56 placebo 56 mg dose 55 dosing regimens 55 statistically significant reduction 55 Phase 2b study 55 endpoints 55 Phase IIb clinical 54 placebo controlled 54 LEVADEX 54 randomized placebo controlled 53 statistically significant 53 mg doses 53 tolerability profile 53 Phase IIa clinical 53 DSMB 53 pivotal Phase III 53 Phase IIa trial 52 Phase 2a clinical 52 unblinded 52 Phase 2a 52 Phase 2b clinical 52 Phase IIa 52 Phase 2b 52 free survival PFS 52 pharmacokinetic 52 efficacy 52 Phase 1b 52 p = #.# [002] 52 randomized controlled 51 RG# [001] 51 monotherapy 51 daclizumab 51 Phase III clinical 51 LymphoStat B 51 pivotal Phase 51 randomized 51 Phase IIb 51 PRX # 51 Phase IIb trial 51 clinically relevant 51 Phase 2b trial 51 reach statistical significance 51 randomized double 51 Zenvia 50 HbA1c 50 double blind placebo 50 pharmacokinetic profile 50 Phase Ib 50 dose regimen 50 placebo p 49 INCB# [002] 49 oral dosing 49 dosing regimen 49 CRx 49 pharmacodynamics 49 placebo p = 49 sunitinib 49 sitagliptin 49 rosuvastatin 49 dosing 49 pegylated interferon 49 blind randomized 49 antitumor activity 49 HCV RNA 49 copies mL 49 blind randomized placebo 49 pharmacokinetics 49 linaclotide 49 endpoint 49 Phase III 49 Locteron 49 dose escalation 48 bortezomib 48 infliximab 48 post hoc 48 ADX# 48 TMC# [001] 48 avanafil 48 Phase III trials 48 AZD# 48 bioequivalence 48 pioglitazone 48 randomization 48 plasma concentrations 48 JANUVIA 48 certolizumab pegol

Back to home page